Symphony Health Solutions Appoints Frank Lavelle Chief Executive Officer

Industry Leader to Drive Customer-Centric Innovation for Information and Analytics Business

Phoenix, Arizona, UNITED STATES

HORSHAM, Pa. and PHOENIX, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Symphony Health Solutions, a provider of high-value data, analytics, and technology based solutions for life science manufacturers, payers and providers, today announced the appointment of Frank Lavelle as Chief Executive Officer. Launched in May 2012, Symphony Health Solutions was formed by the Symphony Technology Group (STG) by combining four complementary healthcare insight companies, including AlphaDetail, ImpactRx, Source Healthcare Analytics and TargetRx, into a single customer-centric firm focused on innovating the industry.

Lavelle is a seasoned executive in the healthcare market having served as the CEO for Siemens Medical Solutions and President for Medquist, with an excellent record of creating growth and profitability at each organization under his leadership. For the past four years Lavelle served as the President and CEO of SunGard Data Systems' K12 division, which provided technology solutions for the primary education marketplace. His background in both technology-enabled data solutions and healthcare provides a unique blend of knowledge that will enable him to understand and grow the business in new directions to meet and anticipate the needs of Symphony Health Solutions' customers.

"Frank Lavelle is a great leader who blends intense customer focus and strategic acumen.  In particular, his track record of leading organizations with strong customer intimacy as a key driver of success is a perfect match for us in his new role as CEO of Symphony Health Solutions," said Dr. Romesh Wadhwani, Chairman and CEO of STG. "Frank will be instrumental in leading Symphony Health Solutions to become the technology-driven market leader in differentiated data, research and analytics, with a laser focus on customer value creation.  His relentless pursuit of excellence will drive our organization to achieve the highest quality execution, and innovation to fuel growth."

"Quality management of the healthcare ecosystem to drive down expense while improving care is the only viable future for U.S. healthcare," said Frank Lavelle, CEO, Symphony Health Solutions.  "Healthcare data and insights are critical for not just for biopharma commercial organizations, but also communities, payers, providers and all manufacturers to understand and manage the business of health in a whole new way. The transformation of raw data to usable information to gain profound understanding is what we are all about.  We will be relentlessly focused on delivering insights that enable our customers to make informed healthcare and business decisions in a daringly different way."

Symphony Health Solutions is comprised of Source Healthcare Analytics, ImpactRx, TargetRx and AlphaDetail.  The businesses are now integrated with a focus on strong joint value propositions for clients and innovation.  

About Symphony Health Solutions

Symphony Health Solutions enables the growth of our clients and transformation of the healthcare ecosystem by providing best-in-class information, analytics and technology solutions with actionable insights for maximum impact. Comprised of AlphaDetail, ImpactRx, and Source Healthcare Analytics, the company connects and integrates a broad set of primary and secondary health research, analytics and consulting expertise to deliver high-value knowledge products that help our clients leverage the rich data available to transform their businesses.   For more information, visit:

About Symphony Technology Group

Symphony Technology Group (STG) (Palo Alto, CA) is a strategic private equity firm with the mission of investing in and being a partner in building great software and services companies. In addition to capital, STG provides transformation expertise to enable its portfolio companies to deliver more value to clients to retain and attract the best talent, and to achieve best-in-class business performance. All STG portfolio companies are expected to grow through innovation. STG's current portfolio consists of 15 global companies with combined revenue of $2.5 Billion, and 15,000 employees spread evenly across North America, Europe and Asia. For more information, visit:


Contact Data